Showing 4611-4620 of 9330 results for "".
- Merz North America Introduces Mederma PMhttps://practicaldermatology.com/news/20140331-merz_north_america_introduces_mederma_pm/2459290/The makers of Mederma introduced Mederma PM Intensive Overnight Scar Cream, a new scar cream formulated to work at night, when skin naturally regenerates faster. Mederma PM is clinically shown to improve the overall appearance, size, color and texture of scars, making them so…
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent program where physicians are able to select the benefits, determine the deta…
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American A…
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (hives) and is not for use in ch…
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phase 2 study was a double blind, vehicle-controlled, dose-ranging …
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new line will launch o…
- FDA approves Impavido to treat tropical disease leishmaniasishttps://practicaldermatology.com/news/20140320-fda_approves_impavido_to_treat_tropical_disease_leishmaniasis/2459308/The US Food and Drug Administration approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and…
- Ferndale Healthcare Announces Partnership with Colon Cancer Alliancehttps://practicaldermatology.com/news/20140318-ferndale_healthcare_announces_partnership_with_colon_cancer_awareness/2459313/Ferndale Healthcare's RectiCare® Cream, intended to resolve all discomfort from rectal and anal conditions such as hemorrhoids and anal fissures, urges colon screening for cancer before individuals reach for their brand. The brand wants to promote individuals to not rush to treat when bleeding and …
- Valeant Pharmaceuticals Donates $250,000 to The National Coalition Against Domestic Violencehttps://practicaldermatology.com/news/20140317-valeant_pharmaceuticals_donates_250000_to_the_national_coalition_against_domestic_violence/2459314/Valeant Pharmaceuticals North America, LLC donated $250,000 to the National Coalition Against Domestic Violence (NCADV). The donation is a reflection of Valeant's ongoing support and commitment to the wellbeing of women, and is the first of four checks the company will present to NCADV in a one-yea…
- Antares Pharma Announces LEO Pharma's Launch of Otrexup (Methotrexate) Injection for Adults with Psoriasishttps://practicaldermatology.com/news/20140311-antares_pharma_announces_leo_pharmas_launch_of_otrexup_methotrexate_injection_for_adults_with_psoriasis/2459320/Antares Pharma, Inc. announced LEO Pharma's launch of Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. "We are very pleased that Otrexup is now available for adult patients …